Ginkgo Bioworks Holdings, Inc. operates as a horizontal platform for cell programming, providing end-to-end services for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatic testing products and services primarily provided to public health authorities. We show 11 historical shares outstanding datapoints in our DNA shares outstanding history coverage, used to compute DNA market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing DNA market cap history over the course of time is important for investors
interested in comparing DNA's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of DNA versus a peer is one thing; comparing
DNA market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like DNA can fluctuate over the course of history.
With this page we aim to empower investors researching DNA by allowing them to research the DNA market cap history. |
Free DNA Email Alerts:
Video: The Importance of Market Cap
